Nchi: Singapoo
Lugha: Kiingereza
Chanzo: HSA (Health Sciences Authority)
FLUCONAZOLE
PFIZER PRIVATE LIMITED
J02AC01
200 mg/5 ml
SUSPENSION
FLUCONAZOLE 200 mg/5 ml
ORAL
Prescription Only
Fareva Amboise
ACTIVE
1996-09-04
1. NAME OF THE MEDICINAL PRODUCT DIFLUCAN 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DIFLUCAN contains as its active ingredient fluconazole 50 mg, 100 mg, 150 mg and 200 mg as capsules, 50 mg or 200 mg per 5 ml as powder for oral suspension on reconstitution with water, and as 2 mg/ml in a saline solution for intravenous infusion. 3. PHARMACEUTICAL FORM Capsule, powder for oral suspension, solution for intravenous infusion. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. 1. Cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g., pulmonary, cutaneous). Normal hosts and patients with AIDS, organ transplants or other causes of immunosuppression may be treated. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS. 2. Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infection. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. Patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. Mucosal candidiasis. These include oropharyngeal, esophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated. 4. Genital candidiasis. Vaginal c Soma hati kamili
1. NAME OF THE MEDICINAL PRODUCT DIFLUCAN 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DIFLUCAN contains as its active ingredient fluconazole 50 mg, 100 mg, 150 mg and 200 mg as capsules, 50 mg/5 ml or 200 mg/5 ml as powder for oral suspension on reconstitution with water, and as 2 mg/ml in a saline solution for intravenous infusion. 3. PHARMACEUTICAL FORM Capsules, powder for oral suspension, solution for intravenous infusion. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. 1. Cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g., pulmonary, cutaneous). Normal hosts and patients with AIDS, organ transplants or other causes of immunosuppression may be treated. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS. 2. Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infections. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. Patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. Mucosal candidiasis. These include oropharyngeal, esophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated. 4. Genital candidiasis. Vaginal candidiasis, acute or recurrent. 5. Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy. 6. Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, and dermal _Candida_ infections. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Th Soma hati kamili